July 5, 2017

Injeq bags big money

Injeq IQ-Needle and BZ-301 analyser promise to enable "a smoother and faster puncture".
Injeq IQ-Needle and BZ-301 analyser promise to enable "a smoother and faster puncture".
Injeq

Medical device company Injeq has closed a share issue that speeds up the European market entry for its first product, Injeq IQ-Needle.

Initially, Injeq’s target sum was 250 000 euros, but according to the campaign site on Invesdor, the round closed with 1 655 360 euros invested in the company.

Injeq develops bioimpedance based tissue identification, and its Injeq IQ-Needle is currently in clinical trials. The needle, equipped with electrodes and Injeq BZ-301 analyser for advanced real-time information, immediately alerts the physician as the tip of the needle reaches the spinal fluid. This helps avoid excessive needle penetration.

The technology can be used in various clinical applications, including regional anesthesia and biopsy. The products are expected to improve diagnosis, reduce complications and enable new type of treatments.

Last month, before the round closed, Injeq announced the expansion of clinical trials to three hospitals in Denmark (Copenhagen University Hospital), Norway (Haukeland University Hospital) and Sweden (Karolinska University Hospital).

“International studies are an important step in demonstrating the benefits of Injeq IQ-Needle,” said Dr. Rami Lehtinen, VP clinical development & sales, at the time. “We are happy and honoured to enter research collaboration with leading children’s hospitals in Scandinavia. Preparations and planning for new studies has now been started.”

Looking for more good news? Subscribe to our newsletter

Share: